We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App

Fast, Fully Automated Microfluidic Device Predicts Effectiveness of Cancer Treatment

By LabMedica International staff writers
Posted on 03 Apr 2023
Print article
Image: New microfluidics physics-based device to predict cancer therapy response (Photo courtesy of University of Barcelona)
Image: New microfluidics physics-based device to predict cancer therapy response (Photo courtesy of University of Barcelona)

Designing new technologies for personalized cancer treatment is a significant challenge in the ongoing battle against cancer. Tumors possess unique characteristics and predictive indicators of a patient's response to treatment, based on the tumor's molecular characteristics, such as DNA mutations, is a crucial step forward in oncology. Precision medicine seeks to provide a tailored treatment for cancer patients, both adult and pediatric, that is specific to their pathology. Determining whether a patient can benefit from a particular treatment before initiating therapy could provide a boost to personalized cancer treatment. Now, a microfluidic device can quickly and automatically predict the effectiveness of cancer treatment by using a tiny amount of cells from biopsies and without the need for specialized technical staff.

The microfluidic device called microfluidic dynamic BH3 profiling (μDBP) has been developed by researchers at the University of Barcelona (Barcelona, Spain) and the Institute for Bioengineering of Catalonia (IBEC, Barcelona, Spain). The dynamic BH3 profiling (DBP) was among the first functional assays to be successfully tested for predicting treatment in various types of cancer. This system exposes cancer cells to different therapeutic options to quickly identify the most effective treatment for a patient. This approach is conceptually similar to the use of antibiograms to identify appropriate antibiotics for bacterial infections. However, the μDBP microfluidic device represents a significant improvement over previous DBP systems. This new device requires fewer cancer cells to test potential therapies, automates the process, and can be used without requiring specialized technical staff, making it easier to apply in a clinical setting.

The initial step in testing a biopsy sample involves dissociating it into individual cells using mechanical and enzymatic methods. The processed sample is then filtered to obtain individual cells, which are subjected to the desired treatments before being seeded into the microfluidic device. The use of the μDBP microfluidic platform, which contains small wells for cell seeding, reduces the number of cells required to test a treatment, making it possible to test a larger number of drugs, which is a significant breakthrough. The paper published in the journal npj Precision Oncology is the first to use microfluidics for performing the functional assay of the DBP. Unlike other versions of the assay that require expensive machinery and specialized staff, such as the high-throughput DBP with automated plates and dispensers that test hundreds of treatments, the new μDBP device is designed to test treatments in situ quickly, easily, and automatically, without the need for expensive machinery or specialized staff. The team is currently working on a new prototype of the μDBP device that incorporates technical improvements and aims to gather more experimental evidence with primary samples to demonstrate its clinical usefulness in improving the treatment of various cancers, both pediatric and adult.

“The biggest advantage of the μDBP device is also the automation of the whole process, which would help to implement this functional methodology on a clinical scale. All these advantages would ease the adoption of DBP in hospitals as a routine trial,” according to the researchers.

“DBP has been used to identify the efficacy of treatments on a preclinical and clinical scale in many different cancers, both solid and liquid. These studies have used cell lines, animal models and primary samples with high predictive ability in all cases. However, this assay has not yet been widely applied in hospitals,” said lecturer Joan Montero. “So far, several studies have found a good correlation between DBP results and clinical response in primary leukemia samples. There are currently several clinical trials underway, and we would like this technology to be implemented in hospitals in the coming years to improve cancer therapies.”

Related Links:
University of Barcelona 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Hemoglobin Testing System

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.